Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability

Title of the cohort
Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability
Acronym for cohort
FINGER
Name of Principal Investigator

Title Docent, Ass Professor
First name Miia
Last name Kivipelto

Address of institution where award is held

Institution Univeristy of Eastern Finland
Street Address Yliopistonranta 1 B
City Kuopio
Postcode 70211

Country

  • Finland

Website
www.thl.fi/finger
Contact email
[email protected]
Funding source
Academy of Finland
Kuopio Univeristy Hospital
Univeristy of Eastern Finland
Alzheimer Association USA
1. The cohort includes, or expects to include, incidence of the following conditions

  • Alzheimer’s disease and other dementias

When studies on the above condition(s) are expected to become possible

  • 2011 – 2015

2a. Stated aim of the cohort
Multimodal intervention study in subjects with increased risk for Alzheimer’s disease and with slight memory impairment.
2b. Features distinguishing this cohort from other population cohorts
Multimodal 2-year intervention study in subjects with increased risk for Alzheimer’s disease and with slight memory impairment.
3a. i) Number of publications that involve use of cohort to date

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort

4a. Study criteria: age range of participants at recruitment

Age in years from: 60-75 years
To (‘until death’ if applicable):

4b. Study criteria: inclusion criteria
High dementia risk score (Kivipelto et al 2006) and objective evidenced memory /
cognitive impairment
4c. Study criteria: exclusion criteria
Dementia, any major disease preventing participation in the intervention
5. Size of the cohort (i.e. number of participants enrolled)

  • 1,000 – 5,000 participants

6a. Measures used to characterise participants
Demographic, health, cognition, functional capacity, cardiovascular fitness parameters…
6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

  • No

7. Study design

  • Other (please specify)
  • Randomized intervention study

8. Cases matched by

  • Age
  • Sex

9a. Does the study include a specialised subset of control participants

  • No

9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date
01-09-2009
10a. ii) Data collection end date
31-12-2013
10a iii) Data collection for this study is

  • Data collection ongoing

10b. Plans to continue the cohort study beyond the current projected end date

  • Yes – intend to apply for funding

11. Data collected

  • Only through the study
  • Through links to medical records
  • Through links to other records or registers (such as dental records, police records etc). Please specify
  • ###VALUE###

12. System in place to enable re-contact with patients for future studies

  • Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

Yes/No % available
Data summarised in database
Database is web-based  Yes
Database on spreadsheet
Database is on paper  No
Other (specify)

 
Language used:
Finnish /English
13b. Format and availability of data held as individual records

Yes/No % available
Data held as individual records  Yes
Data is web-based Yes
Data held on computer based records  Yes
Data held on cards
Other (specify)

 
Language used:
Finnish /English
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups

  • Access through collaboration with PI only

15. Data sharing policy specified as a condition of use

  • No requirement to make data publicly available

16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA

  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups

  • No

Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability

Population Cohorts
Finland
Alzheimer’s disease & other dementias
2011

 

 

Post
Filter